Rakovina Therapeutics Inc.
RKV.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 334.64% | 358.32% | 161.25% | 61.90% | 40.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 269.63% | 187.30% | 104.94% | 57.81% | 26.87% |
| Operating Income | -269.63% | -187.30% | -104.94% | -57.81% | -26.87% |
| Income Before Tax | -251.50% | -172.16% | -99.53% | -54.41% | -33.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -251.50% | -172.16% | -99.53% | -54.41% | -33.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.50% | -172.16% | -99.53% | -54.41% | -33.97% |
| EBIT | -269.63% | -187.30% | -104.94% | -57.81% | -26.87% |
| EBITDA | -327.79% | -233.97% | -132.59% | -75.48% | -35.36% |
| EPS Basic | -56.25% | -35.55% | -39.21% | -20.12% | -32.29% |
| Normalized Basic EPS | -56.23% | -35.34% | -37.47% | -20.14% | -32.17% |
| EPS Diluted | -51.08% | -75.13% | -71.45% | -11.26% | -17.88% |
| Normalized Diluted EPS | -56.23% | -35.34% | -37.47% | -20.14% | -32.17% |
| Average Basic Shares Outstanding | 125.00% | 100.86% | 43.36% | 28.45% | 1.29% |
| Average Diluted Shares Outstanding | 125.00% | 100.86% | 43.36% | 28.45% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |